Briggs Morrison - 05 Jun 2025 Form 3/A - Amendment Insider Report for CRISPR Therapeutics AG (CRSP)

Role: Director
Signature: /s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol: CRSP
Transactions as of: 05 Jun 2025
Net transactions value: $0
Form type: 3/A - Amendment
Filing time: 10 Jun 2025, 17:31:03 UTC
Date Of Original Report: 06 Jun 2025
Previous filing: 27 Jun 2024
Next filing: 13 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Morrison Briggs	Director	C/O CRIPSR THERAPEUTICS, 105 WEST FIRST STREET, BOSTON	/s/ Elizabeth Ryland Waldinger, attorney-in-fact	10 Jun 2025	0001654430

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	CRSP	Common Shares						5,209	05 Jun 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CRSP	Stock Option (Right to Buy)							05 Jun 2025	Common Shares	26,000	$48.68	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Form 3 filed on June 6, 2025 for the Reporting Person reported an incorrect number of shares held by the Reporting Person as of June 5, 2025. This amended Form 3 is being filed to correct such number of shares held by the Reporting Person as of June 5, 2025.
F2	This option was granted on December 10, 2024 with respect to 26,000 Common Shares. 100% of the shares will vest in 36 equal monthly installments, with the first vesting date of January 10, 2025.

Remarks:

This amendment is being filed solely to correct the reporting of ownership of certain Common Shares reported in Table I. See Footnote 1 hereto.